Prothena Corp Plc (PRTA):企業の財務・戦略的SWOT分析

◆英語タイトル:Prothena Corp Plc (PRTA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14815
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products include PRX002, that targets alpha -synuclein protein for the treatment of Parkinson’s disease and other synucleinopathies; NEOD001, that targets the circulating soluble and deposited aggregated amyloid in the treatment of primary systemic amyloidosis; PRX004, indicated to clear the misfolded (toxic) forms of the TTR amyloid protein in Transthyretin amyloidosis (ATTR amyloidosis). Protena also develops several discovery-stage programs in collaboration with other pharmaceurtical companies for neurodegenerative or orphan diseases such as Alzheimer’s disease (AD), ALECT2 amyloidosis, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Prothena is headquartered in Dublin, Ireland.

Prothena Corp Plc Key Recent Developments

Feb 14,2019: Prothena reports fourth quarter and full year 2018 financial results, and provides financial guidance and R&D update
Jan 07,2019: Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology
Nov 07,2018: Prothena reports third quarter 2018 financial results and provides R&D update
Aug 07,2018: Prothena reports second quarter 2018 financial results and provides R&D update

This comprehensive SWOT profile of Prothena Corp Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Prothena Corp Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Prothena Corp Plc – Key Information
Prothena Corp Plc – Overview
Prothena Corp Plc – Key Employees
Prothena Corp Plc – Key Employee Biographies
Prothena Corp Plc – Key Operational Heads
Prothena Corp Plc – Major Products and Services
Prothena Corp Plc – History
Prothena Corp Plc – Company Statement
Prothena Corp Plc – Locations And Subsidiaries
Prothena Corp Plc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Prothena Corp Plc – Business Description
Prothena Corp Plc – Corporate Strategy
Prothena Corp Plc – SWOT Analysis
SWOT Analysis – Overview
Prothena Corp Plc – Strengths
Prothena Corp Plc – Weaknesses
Prothena Corp Plc – Opportunities
Prothena Corp Plc – Threats
Prothena Corp Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Prothena Corp Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Prothena Corp Plc, Key Information
Prothena Corp Plc, Key Ratios
Prothena Corp Plc, Share Data
Prothena Corp Plc, Major Products and Services
Prothena Corp Plc, History
Prothena Corp Plc, Key Employees
Prothena Corp Plc, Key Employee Biographies
Prothena Corp Plc, Key Operational Heads
Prothena Corp Plc, Other Locations
Prothena Corp Plc, Subsidiaries
Prothena Corp Plc, Key Manufacturing facilities
Prothena Corp Plc, Key Competitors
Prothena Corp Plc, SWOT Analysis
Prothena Corp Plc, Ratios based on current share price
Prothena Corp Plc, Annual Ratios
Prothena Corp Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Prothena Corp Plc, Performance Chart
Prothena Corp Plc, Ratio Charts

★海外企業調査レポート[Prothena Corp Plc (PRTA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Perenco Holdings:企業の戦略的SWOT分析
    Perenco Holdings - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Doosan Heavy Industries & Construction Co Ltd (034020)-エネルギー分野:企業M&A・提携分析
    Summary Doosan Heavy Industries & Construction Co., Ltd. (Doosan Heavy Industries), a subsidiary of Doosan Corporation, is a power plant equipment manufacturer. It offers integrated equipment and solutions for power and water plants. The company’s major products include boilers, generators, engines, …
  • Eurofins Scientific SE:戦略・SWOT・企業財務分析
    Eurofins Scientific SE - Strategy, SWOT and Corporate Finance Report Summary Eurofins Scientific SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Stentys SA (STNT):企業の財務・戦略的SWOT分析
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …
  • Immune Therapeutics Inc (IMUN):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Therapeutics Inc (IMUN), formerly pH Environmental Inc, is a specialty pharmaceutical company that discovers, develops and commercializes patented therapies and technology such as Lodonal, LDN, CAR-T and MENK. The company’s patented therapies are focused on the activation and re-balan …
  • Titanium Metals Corporation:企業の戦略・SWOT・財務情報
    Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report Summary Titanium Metals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Astea International Inc (ATEA):企業の財務・戦略的SWOT分析
    Summary Astea International Inc (Astea) is a technology company that offers end-to-end service management software solutions. The company offers products such as Astea Alliance and FieldCentrix. Its FieldCentrix is used in paper-based operation, optimizes service resources, and provides standardized …
  • BioRestorative Therapies Inc (BRTX):企業の財務・戦略的SWOT分析
    Summary BioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance Inc is a developer of therapeutic products and medical therapies. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is designed to offer a non-surgical treatment …
  • Bayer AG (BAYN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • Nord Gold SE:企業の戦略・SWOT・財務分析
    Nord Gold SE - Strategy, SWOT and Corporate Finance Report Summary Nord Gold SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CCP Technologies Ltd (AGX)-製薬・医療分野:企業M&A・提携分析
    Summary CCP Technologies Ltd (CCP), formerly Agenix Ltd is a biotechnology company that offers molecule drugs. The company develops small molecule drugs and monoclonal antibody-based diagnostics for the treatment of various diseases. It develops DiagnostIQ rapid point-of-care human diagnostic techno …
  • Business Development Bank Of Canada
    Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report Summary Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Vetoquinol SA (VETO):企業の財務・戦略的SWOT分析
    Summary Vetoquinol SA (Vetoquinol) is a veterinary pharmaceutical company that develops, produces and distributes veterinary drugs and non-medicinal products. The company provides pain management, anti-infective, hygiene and care, pest control, behavior, internal medicine, reproduction, behaviour an …
  • MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析
    Summary MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs such as MN-001, for the treatm …
  • Sbarro, LLC:企業の戦略・SWOT・財務情報
    Sbarro, LLC - Strategy, SWOT and Corporate Finance Report Summary Sbarro, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Hetero Drugs Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom …
  • Inivata Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in …
  • APRIL Group S.A. (APR):企業の財務・戦略的SWOT分析
    APRIL Group S.A. (APR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Drummond Company Inc:企業の戦略・SWOT・財務情報
    Drummond Company Inc - Strategy, SWOT and Corporate Finance Report Summary Drummond Company Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Toyota Tsusho Corporation:戦略・SWOT・企業財務分析
    Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆